A Study of NKTR-358 (LY3471851) in Healthy Participants
A Phase 1, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous Dose of NKTR-358 in Healthy Volunteers
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Kansas
-
Lenexa, Kansas, United States, 66219
- PRA Health Sciences
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Overtly healthy males and females, as determined by medical history and physical examination
- Have a body mass index (BMI) of 18.0 to 32.0 kilograms per square meter (kg/m²)
Exclusion Criteria:
- Previous or current autoimmune disease/disorder
- Current active bacterial, viral, or fungal infection
- Administration of an inactivated vaccine within two weeks of study drug administration or live attenuated vaccine within 90 days of dosing .
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: LY3471851
Healthy participants in each cohort will receive single subcutaneous (SC) doses of LY3471851.
|
LY3471851 drug product is a sterile liquid for SC injection that may be diluted with sterile 0.9% sodium chloride solution for injection (USP) prior to administration.
Other Names:
|
|
Placebo Comparator: Placebo
Healthy participants in each cohort will receive the placebo comparator.
|
The placebo dosing solution is 0.9% sodium chloride for injection (USP).
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Time Frame: Baseline up to Day 50
|
Number of Participants with One or More SAEs Considered by the Investigator to be Related to Study Drug Administration
|
Baseline up to Day 50
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3471851
Time Frame: Predose on Day 1 through Day 50
|
PK: Cmax of LY3471851
|
Predose on Day 1 through Day 50
|
|
PK: Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC[0-inf]) of LY3471851
Time Frame: Predose on Day 1 through Day 50
|
PK: (AUC[0-inf]) of LY3471851
|
Predose on Day 1 through Day 50
|
|
Pharmacodynamics (PD): Mean Change from Baseline in Regulatory T cells (Tregs)
Time Frame: Predose on Day 1 through Day 50
|
PD: Mean change from baseline in Tregs
|
Predose on Day 1 through Day 50
|
|
PD: Change from Baseline in Treg Activation Markers
Time Frame: Predose on Day 1 through Day 50
|
PD: Treg activation markers include: Cytokine levels, conventional CD4+ and CD8+ Tcells, and natural killer (NK) cells
|
Predose on Day 1 through Day 50
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Study Director, Nektar Therapeutics
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 17237 (Other Identifier: City of Hope Medical Center)
- J1P-MC-KFAA (Other Identifier: Eli Lilly and Company)
- 16-358-01 (Other Identifier: Nektar Therapeutics)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.